公开(公告)号：US20180346486A1

公开(公告)日：2018-12-06

申请号：US16002007

申请日：2018-06-07

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit C. DESAI ,  Brijeshkumar SRIVASTAVA

IPC: C07D513/04 ,  C07F3/00 ,  A61K31/40 ,  C07D209/44 ,  C07D295/096 ,  C07D491/048 ,  C07D207/06 ,  C07D209/12 ,  C07D498/04 ,  C07D495/04 ,  C07D207/20 ,  C07D207/08 ,  C07D491/04 ,  C07D487/04 ,  C07D471/04 ,  C07D217/04 ,  C07D215/20 ,  C07D215/06 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/472 ,  A61K31/47 ,  A61K31/439 ,  A61K31/437 ,  A61K31/4365 ,  A61K31/4162 ,  A61K31/407 ,  A61K31/404 ,  C07D491/08 ,  A61K31/496 ,  A61K31/4453 ,  A61K31/4375 ,  A61K31/435 ,  C07D209/08

CPC classification number: C07D513/04 ,  A61K31/40 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/435 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  C07D207/06 ,  C07D207/08 ,  C07D207/20 ,  C07D209/08 ,  C07D209/12 ,  C07D209/44 ,  C07D215/06 ,  C07D215/20 ,  C07D217/04 ,  C07D295/096 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D495/04 ,  C07D498/04 ,  C07F3/00

Abstract: The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo [3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.

公开(公告)号：US20160376277A1

公开(公告)日：2016-12-29

申请号：US15112536

申请日：2015-02-02

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit C. DESAI ,  Rajesh BAHEKAR ,  Dipam PATEL ,  Kiran SHAH

IPC: C07D487/04 ,  A61K31/4985 ,  A61K31/55 ,  A61K31/522 ,  A61K31/5377 ,  C07D473/34 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D473/34

Abstract: The present invention relates to heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as selective Bruton's Tyrosine Kinase (BTK) inhibitors.

Abstract translation: 本发明涉及通式（I）的药学上可接受的盐，药学上可接受的溶剂合物，对映异构体，非对映体和多晶型物的杂环化合物。 本发明还涉及制备本发明化合物的方法，含有该化合物的药物组合物及其作为选择性Bruton's酪氨酸激酶（BTK）抑制剂的用途。（I）

公开(公告)号：US20170105937A1

公开(公告)日：2017-04-20

申请号：US15295235

申请日：2016-10-17

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Shafiq un Nabi SHEIKH ,  Mukesh UKAWALA ,  Tishir GANDHI ,  Brijesh Kumar SRIVASTAVA ,  Muthaiyyan Essakimuthu KANNAN ,  Ranjit C. DESAI

IPC: A61K9/14 ,  A61K47/38 ,  A61K31/502

CPC classification number: A61K9/146 ,  A61K9/2054 ,  A61K9/4866 ,  A61K31/502

Abstract: The present invention relates to co-precipitates of olaparib and an ionic polymer and pharmaceutical composition containing the co-precipitates. Further, the present invention relates to a method of treating disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said composition.

公开(公告)号：US20170007610A1

公开(公告)日：2017-01-12

申请号：US15113497

申请日：2015-01-23

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit C. DESAI ,  Rajesh BAHEKAR ,  Vijay PRAJAPATI ,  Pankaj R. PATEL

IPC: A61K31/517 ,  C07D401/12 ,  A61K31/4709 ,  A61K31/4725 ,  C07D405/12 ,  C07D401/14 ,  C07D403/12 ,  A61K31/498 ,  A61K31/404 ,  C07D513/06 ,  A61K31/437 ,  A61K45/06 ,  A61K31/4025

CPC classification number: A61K31/517 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D513/06 ,  C07D513/14

Abstract: The present invention relates to novel compounds of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (κ) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.

Abstract translation: 本发明涉及通式（I）的新型化合物，其是选择性和外周作用的KOR激动剂，它们的互变异构形式，它们的对映体，它们的非对映异构体，它们的立体异构体，其药学上可接受的盐或前药，其可用于 治疗或预防其中涉及“卡帕（κ）阿片受体（KOR）”的疾病，例如治疗或预防内脏痛，痛觉过敏，类风湿关节炎，骨关节炎，IBD炎症，IBS炎症，眼部炎症，耳炎 本发明还涉及制备所述化合物的方法和含有它们的药物组合物及其用途。

公开(公告)号：US20160257701A1

公开(公告)日：2016-09-08

申请号：US15034661

申请日：2014-11-03

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit C. DESAI ,  Brijeshkumar SRIVASTAVA

IPC: C07D513/04 ,  C07D491/048 ,  C07D487/04 ,  C07D471/04 ,  C07D209/44 ,  C07D215/06 ,  C07F3/00 ,  C07D491/08 ,  C07D498/04 ,  C07D295/096 ,  C07D217/04 ,  C07D209/08 ,  C07D215/20 ,  C07D207/08 ,  C07D207/06 ,  C07D495/04

CPC classification number: C07D513/04 ,  A61K31/40 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/435 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/472 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/519 ,  C07D207/06 ,  C07D207/08 ,  C07D207/20 ,  C07D209/08 ,  C07D209/12 ,  C07D209/44 ,  C07D215/06 ,  C07D215/20 ,  C07D217/04 ,  C07D295/096 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D491/08 ,  C07D495/04 ,  C07D498/04 ,  C07F3/00

Abstract: The present invention relates to novel GPR 40 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.

Abstract translation: 本发明涉及通式（I）的新型GPR 40激动剂，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，其制备方法，这些化合物在医药中的用途以及涉及 他们的准备。

公开(公告)号：US20160083380A1

公开(公告)日：2016-03-24

申请号：US14888377

申请日：2014-12-15

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit C. DESAI ,  Harikishore PINGALI

IPC: C07D471/04 ,  A61K31/41 ,  A61K45/06 ,  C07D249/08 ,  A61K31/4196 ,  C07D249/04 ,  A61K31/4192 ,  C07D271/10 ,  A61K31/4245 ,  C07D285/12 ,  A61K31/433 ,  C07D271/06 ,  C07D263/04 ,  A61K31/421 ,  C07D401/12 ,  A61K31/4439 ,  C07D307/42 ,  A61K31/341 ,  A61K31/437 ,  C07D257/04

CPC classification number: C07D471/04 ,  A61K31/341 ,  A61K31/41 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4439 ,  A61K45/06 ,  C07D249/04 ,  C07D249/08 ,  C07D257/04 ,  C07D263/04 ,  C07D263/32 ,  C07D271/06 ,  C07D271/10 ,  C07D285/12 ,  C07D307/12 ,  C07D307/42 ,  C07D401/12

Abstract: Compounds of the general formula (I), including their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds and the intermediates involved in their preparation.

Abstract translation: 通式（I）的化合物，包括其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，其制备方法，这些化合物的用途和参与其制备的中间体。